The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma
Open accessAbstract
Lenvatinib is an inhibitor of multiple receptor tyrosine kinases that was recently authorized for first-line treatment of hepatocellular carcinoma (HCC). However, the clinical benefits derived from lenvatinib are limited, highlighting the urgent need to understand mechanisms of resistance. We report here that HCC cells develop resistance to lenvatinib by activating EGFR and stimulating the EGFR–STAT3–ABCB1 axis. Lenvatinib resistance was accompanied by aberrant cholesterol metabolism and lipid raft activation. ABCB1 was activated by EGFR in a lipid raft–dependent manner, which significantly enhanced the exocytosis of lenvatinib to mediate resistance. Furthermore, clinical specimens of HCC showed a correlation between the activation of the EGFR–STAT3–ABCB1 pathway and lenvatinib response. Erlotinib, an EGFR inhibitor that has also been shown to inhibit ABCB1, suppressed lenvatinib exocytosis, and combined treatment with lenvatinib and erlotinib demonstrated a significant synergistic effect on HCC both in vitro and in vivo. Taken together, these findings characterize a mechanism of resistance to a first-line treatment for HCC and offer a practical means to circumvent resistance and treat the disease. Significance: HCC cells acquire resistance to lenvatinib by activating the EGFR–STAT3–ABCB1 pathway, identifying combined treatment with erlotinib as a strategy to overcome acquired resistance and improve the clinical benefit of lenvatinib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Lipid rafts as a membrane-organizing principle
Lingwood, D., & Simons, K. (2010) · Science · doi:10.1126/science.1174621 · Cited by 4,417 · cited 1×
“Lipid rafts are a 10 to 200 nm, heterogeneous, highfluidity regions of the cell membrane that are rich in sterols, sphingolipids, and cholesterol (5), and can stably form a platform for the proteins and lipids that participate in a wide range of biological activities (6).”
BackgroundA view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866 · cited 4×
“A variety of receptor tyrosine kinases (RTK) and functional proteins, such as EGFR and ATP-binding cassette (ABC) transporter family members, are concentrated in lipid rafts.”
BackgroundInfluentialThe discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 1×
“The homologous ligands of EGFR include EGF, TGFa, and amphiregulin (9, 10), which induce EGFR homodimerization or heterodimerization and lead to the phosphorylation of intracellular tyrosine residues that activate downstream pathways (such as the RAS–RAF–MEK–ERK, JAK–STAT, and PI3K–AKT pathways) and regulate a variety…”
BackgroundThe Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring
Schlessinger, J., & Lemmon, M. A. (2006) · Cell · doi:10.1016/j.cell.2006.09.013 · Cited by 98
Cited by
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Self-citationZhang, X.-Y., Li, S.-S., Gu, Y.-R., Xiao, L.-X., Ma, X.-Y., Chen, X.-R., Wang, J.-L., Liao, C.-H., Lin, B.-L., Huang, Y.-H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02030-x · Cited by 80
PFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer
Hong, J., Du, K., Zhang, W., Jiang, Y., Yu, H., Pan, T., Wu, T., Zhao, L., Du, W., Zheng, S.-S., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c08669 · Cited by 16
Self-citation
Metadata
- Authors
- Hu, B., Zou, T., Qin, W., Shen, X., Su, Y., Li, J., Chen, Y., Zhang, Z., Sun, H., Zheng, Y., Wang, C.-Q., Wang, Z., Li, T.-E., Wang, S., Zhu, L., Wang, X., Fu, Y., Ren, X., Dong, Q., & Qin, L.-X.
- Venue
- Cancer Research
- Published
- 2022-09-06
- Volume
- 82
- Issue
- 20
- Pages
- 3845-3857
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W4294785826
- Cited by
- 184
- References
- 9
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-4140
- The paper
- Hu, B., Zou, T., Qin, W., Shen, X., Su, Y., Li, J., Chen, Y., Zhang, Z., Sun, H., Zheng, Y., Wang, C.-Q., Wang, Z., Li, T.-E., Wang, S., Zhu, L., Wang, X., Fu, Y., Ren, X., Dong, Q., & Qin, L.-X. (2022). Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-4140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.